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To address the long-known relationship between supernumerary centro-
somes and cancer, we have generated a transgenic mouse that permits
inducible expression of the master regulator of centriole duplication, Polo-
like-kinase-4 (Plk4). Over-expression of Plk4 from this transgene advances
the onset of tumour formation that occurs in the absence of the tumour sup-
pressor p53. Plk4 over-expression also leads to hyperproliferation of cells in
the pancreas and skin that is enhanced in a p53 null background. Pancreatic
islets become enlarged following Plk4 over-expression as a result of equal
expansion of a- and b-cells, which exhibit centrosome amplification. Mice
overexpressing Plk4 develop grey hair due to a loss of differentiated melano-
cytes and bald patches of skin associated with a thickening of the epidermis.
This reflects an increase in proliferating cells expressing keratin 5 in the basal
epidermal layer and the expansion of these cells into suprabasal layers. Such
cells also express keratin 6, a marker for hyperplasia. This is paralleled by a
decreased expression of later differentiation markers, involucrin, filaggrin
and loricrin. Proliferating cells showed an increase in centrosome number
and a loss of primary cilia, events that were mirrored in primary cultures
of keratinocytes established from these animals. We discuss how repeated
duplication of centrioles appears to prevent the formation of basal bodies
leading to loss of primary cilia, disruption of signalling and thereby aberrant
differentiation of cells within the epidermis. The absence of p53 permits cells
with increased centrosomes to continue dividing, thus setting up a neoplastic
state of error prone mitoses, a prerequisite for cancer development.1. Introduction
The centrosome was first described almost simultaneously by Edouard van
Beneden working in Lie`ge and Theodor Boveri in Munich in 1887 (reviewed
in [1]) as a structure at the poles of the mitotic spindle that persisted through
the life cycle of the cell. Towards the end of the nineteenth century tumour
cells were already observed to have multiple spindle poles, and now we
know supernumerary centrosomes to be present in a wide range of solid and
rsob.royalsocietypublishing.org
Open
Biol.5:150209
2haematological tumours, including pancreatic, ovarian, colon
and prostate cancer, multiple myeloma, non-Hodgkin’s and
Hodgkin’s lymphoma, and acute and chronic myeloid leu-
kaemia [2–7]. Abnormalities have been detected at both
early [8–10] and advanced stages of disease where they
generally indicate poor prognosis [11]. Amplified centrosomes
also correlate with metastasis of head and neck, prostate and
breast tumours [12–14]. However, despite these long-known
associations, the contribution of centrosomal amplification to
oncogenesis remains unclear.
Centrosome number is normally tightly controlled within
the cell division cycle. At the core of centrosomes lie the nine-
fold symmetrical centrioles. Cells enter mitosis with two
pairs of orthogonally arranged centrioles that separate to
form the two centrosomes at the poles of the spindle. The
centrioles disengage upon the completion of mitosis
and enable both individual centrioles to initiate the dupli-
cation process. Centriole duplication is controlled by
Polo-like-kinase-4 (Plk4) that phosphorylates the centriole
protein Stil/Ana2 allowing it to recruit Sas6, the core com-
ponent of the centriole cartwheel [15–18]. Elevating Plk4
expression through its ectopic expression or by eliminating
the SCF ubiquitin-protein ligase required for Plk4 destruction
results in the formation of multiple centrosomes [19–23].
The loss of centrioles has different consequences in differ-
ent organisms and tissues. Drosophila can tolerate centriole
loss in some, but not all, tissues, allowing defective cell div-
isions to continue [23–27]. However, centrioles also serve
as basal bodies, the foundations of cilia and flagellae
[28,29], and so are essential to fashion the fly’s sensory
organs for correct physical coordination [24,30]. In mamma-
lian cells, the physical removal of centrosomes prevents cell
cycle progression but eventually centrioles reform by a
de novo pathway and the cell cycle resumes [31–33]. In the
mouse, there is a greater reliance on centrioles to generate pri-
mary cilia essential for many types of cell signalling.
However, unlike mutants that lack cilia, mutant embryos
deficient for the centriole component Sas4 and thereby lack-
ing centrioles exhibit extensive apoptosis associated with
elevated p53 expression [34]. Apoptosis was rescued in
embryos double mutant for Sas4 and p53, thus identifying
a p53-dependent apoptotic pathway triggered by loss of cen-
trioles. This has been further supported by experiments to
eliminate Plk4 activity from cultured cells using either an
auxin-inducible degradation system or pharmacological inhi-
bition of the enzyme using a small molecule, centrinone
[33,35]. In both these cases, loss of Plk4 activity results in
loss of centrioles and a p53-dependent arrest of cell cycle
progression, the mechanism of which is not understood.
The consequences of Plk4 over-expression also vary in
different organisms and in different cell types. Over-expression
or stabilization of Plk4 in either cultured Drosophila cells or
mammalian cells leads to multiple centrosomes [19,21–23,36]
and in fertilized Drosophila eggs drives the formation of thou-
sands of centrioles at the expense of the normal progression of
nuclear division cycles [20]. Strikingly this also happens in
unfertilized eggs in which centrioles have been naturally elimi-
nated during oogenesis and in which there is no incoming
sperm to provide a basal body. Thus, in this circumstance, cen-
triole formation is entirely driven by Plk4. Moreover, elevated
expression of Plk4, and indeed perturbation of centrosome
function through several routes, can promote tumourigenesis
in flies [37,38].Correct centrosome behaviour is also required for the devel-
opment of cerebral cortex of the mammalian brain. Deficiency
of any of several centrosome components including Plk4 results
in microcephaly [39–41]. To study the effects of elevating Plk4
expression in the mouse brain, Marthiens et al. [42] generated
transgenic animals in which Plk4 expression could be activated
in the central nervous system in response to a tissue-specific
Cre-mediated recombination event. This led to a microce-
phaly-like condition that was ascribed to the poor clustering
of amplified centrosomes leading to abnormal mitoses and con-
sequent apoptosis. Cell death could be overcome by removing
p53 function, leading to the accumulation of aneuploidy cells
that would differentiate rather than proliferate.
We wished to examine the consequences of elevated Plk4
expression, and thereby centrosome amplification, in other
tissues in the mouse. To have temporal control on the over-
expression of Plk4, we have developed a mouse line in
which Plk4 is under the control of a doxycycline-inducible
promoter. Induction of Plk4 expression in this mouse leads
to an early onset of tumour formation in p53 null mice,
behavioural defects suggesting abnormalities of brain devel-
opment in agreement with a previous study [39], and
hyperproliferation of cells in the pancreas and in the skin.
Here we focus upon characterizing defects in the skin of these
animals and show that elevated Plk4 leads to amplification of
centrosomes and loss of primary cilia. Together this leads to
both hyperproliferation and uncontrolled differentiation of
the basal epidermis. We discuss how these phenotypes can
arise and how we might account for the enhancement of these
phenotypes when the p53 gene is deleted.2. Results
2.1. Elevated Plk4 expression dramatically advances the
onset of tumour formation in p53-deficient mice
Centrosome amplification has been identified as a marker of
poor prognosis of aggressive, drug-resistant tumours in breast,
pancreatic and colorectal cancer patients [43,44], but the relation-
ship of centriole amplification to oncogenesis is uncertain. To
address this in a model system, we generated a transgenic
mouse that allows the inducible over-expression of wild-type
mPlk4, the master regulator of centriole duplication. The
vector comprised the reverse-tetracycline-controlled transactiva-
tor (rtTA) linked to a tetracycline-responsive element (TRE)
regulating expression of wild-type mPlk4 and was targeted to
the ROSA26 locus. This enabled the inducible and reversible
over-expression of Plk4 at any time of development in the result-
ing transgenic animals or in cultured cells derived from them
(figure 1a). We designate the homozygous transgenic mouse
harbouring the inducible extra copy of wild-type Plk4 as
Plk4OE/ Plk4OE.
As p53 was reported to overcome both the cell cycle arrest
associated with loss of centrioles resulting from deletion of
Sas4 or degradation or inhibition of Plk4 [33–35] and
the cell death resulting from elevated Plk4 expression in the
mouse brain [42], we were prompted also to determine the
consequences of centrosome amplification induced by Plk4
over-expression in a p53 knockout (KO) background (from
now on p53KO). These mice show accelerated tumour for-
mation, behavioural defects and cell hyperproliferation
associated with elevated Plk4 expression in several tissues
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Figure 1. Tumour formation following tetracycline-inducible conditional Plk4 expression. (a) Doxycycline associates with the rtTA that binds the TRE, leading to transcriptional
activation of Plk4. (b) Tumour incidence in Plk4 transgenic mice in wild-type background (Plk4OE/Plk4OE) or p53 null background (Plk4OE/Plk4OE; p53KO/p53KO) with or without
treatment with doxycycline (þDOX) to promote Plk4 over-expression. The differences observed between Plk4OE/Plk4OE; p53KO/p53KO (n¼ 24) and Plk4OE/Plk4OE; p53KO/p53KO
þDOX (n ¼ 14) survival curves are significant (**p, 0.01; Student’s t-test). (c) Proportions of sarcomas and lymphomas. Note that animals that developed sarcomas also
showed lymphomas. (d ) Architecture of thymus and lymph nodes is obliterated and replaced by sheets of large, round cells with vesicular nuclei (Vn, black arrows). Apoptotic
cells were also present (Ap, black asterisk). (e) Multicentric high-grade large cell lymphoma. (f ) Kidney has normal architecture but contains multifocal cortical interstitial and
sub-capsular infiltrates of large lymphocytes (Li). (g) Large sheets of lymphocytes (Li) attached to pericardial surface of heart wall. (h– j ) These tumours are sarcomas isolated
from Plk4OE/Plk4OE; p53KO/p53KO mice. Typically, large masses of cells extended into muscle fibre bundles (M) and into attached adipose surrounding nerves and blood vessels.
(i,j) Higher magnifications of sarcomas showing pleomorphic and anaplastic cells. Examples of giant (G) or multinucleated (MM) cells are indicated. These tumours were found
close to the front limbs with high percentage of mitotic cells (an average of 5–10/40 field). (k) Paraffin section of samples from sarcomas where stained to revealg-tubulin or
acetylated-tubulin (green). DNA is shown in red. Three different samples were analysed and showed a high mitotic index (8.55+ 2.53%, n¼ 1400 cells/sample) in agree-
ment with histological analysis made after H&E staining. (l ) Proportion of cells that show one pair or two pairs of centrioles per cell or show centriole/centrosome amplification
(more than 2 pairs of centrioles). (m) Mitotic progression in sarcomas from cryostat sections. (n) Proportions of mitotic abnormalities in sarcomas. Quantification in
(l–n) performed in three different sarcomas; 500–1000 cells analysed per sarcoma.
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3including the pancreas and skin. Here we describe some key
features of mice that are expressing elevated levels of Plk4
and focus upon how this affects development of the skin
and pancreas.
We first wished to address the effects of Plk4 over-
expression upon tumour formation and so carried outparallel studies on the viability of the Plk4OE/Plk4OE line
with or without the addition of doxycycline (þDOX) to pro-
mote Plk4 over-expression. Plk4OE/Plk4OE and Plk4OE/
Plk4OE (þDOX) mice remained healthy during the period
of study. Litter sizes were reduced in Plk4OE/Plk4OE
(þDOX), but tumour formation was not observed during
rsob.royalsocietypublishing.org
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4the first 35 weeks (figure 1b). We found that approxima-
tely one half of Plk4OE/Plk4OE; p53KO/p53KO mice on a
doxycycline-free diet developed tumours by the age of 20
weeks and all had tumours by 35 weeks. This time course
of tumour appearance parallels previous reports for p53
homozygous null mice [45]. Interestingly, when Plk4
over-expression was induced in the Plk4OE/Plk4OE; p53KO/
p53KO mice by the addition of DOX from eight weeks
onwards, tumour formation was accelerated; half of the
mice developed tumours by 15 weeks and all died within
26 weeks (red line; figure 1b).
The tumours arising in Plk4OE/Plk4OE; p53KO/p53KO mice
were highly similar whether or not doxycycline was adminis-
tered and comprised mainly lymphomas and sarcomas
(figure 1c). The lymphomas invaded a variety of tissues
including the thymus, kidney and heart (figure 1d–g). How-
ever, a wide variety of sarcomas arose more frequently and
earlier after Plk4 over-expression. All animals that succumbed
to sarcomas also had lymphomas. The sarcomas were typically
localized close to the front limbs and developed very rapidly
within one week. These tumours had highly pleomorphic
and anaplastic cells that displayed a high incidence of mitosis
(an average of 5–10 mitotic figures per 40 field) suggesting
they are highly malignant (figure 1h–j) and centrosome amplifi-
cation was detected in 34.79+5.48% of cells from sarcomas
(figure 1l ). The mitotic figures in these Plk4 over-expressing
tumour cells were typically bipolar with multiple centrosomes
at the poles (71%). Centrosome clustering was lost in 12.7+
10.7% of prometaphase cells that were multipolar (figure 1k–n).
Although we failed to detect any multipolar anaphases, we
found chromatid lagging in 23.4+10.6% of anaphase figures
(figure 1n). Itwill be of future interest to identify and characterize
the mesenchymal cells in which these tumours arise.
We conclude that Plk4 over-expression significantly
advances the onset of tumour formation in p53 null mice and
that this is associated with an increased frequency of mitoses
that generate aneuploid cells characteristic of many tumours.2.2. Elevated Plk4 expression induces hyperproliferation
of cells in the pancreas
The above findings raised the question of whether we could
identify any tissues exhibiting common cellular changes
that could be associated with events anticipating tumour
development particularly in the absence of p53 function.
Systematic histological examination of the tissues of
Plk4OE/Plk4OE mice revealed that although pancreases had
normal lobular architecture with intact acinar cell clusters,
there was enlargement of the islets of Langerhans when
over-expression of Plk4 was induced (figure 2a–c,e). The
diameter of the islets was increased by approximately 30%
and the density of cells within the islets more than doubled
under these conditions (figure 2e– f ). To determine whether
this reflected differential proliferation of the major two endo-
crine cell types, we stained pancreas sections with antibodies
against glucagon and insulin to detect a- and b-cells, respect-
ively. This revealed a proportionate increase in the number
of both glucagon- and insulin-positive cells following induc-
tion of Plk4 over-expression (82.8+6.7% b-cells versus
79.8+ 6.0% in Plk4OE/Plk4OE islets without and with DOX,
respectively; figure 2d– f ). Because loss of p53 is known
to exacerbate the effects of both decreased and increasedcentrosome number [33,35,42], we also examined the effects
of Plk4 over-expression on the pancreas in p53 null mice.
Plk4 over-expression now resulted in a more than doubling
in the diameters of the islets although the cell density was
not as high as when p53 was present (figure 2e,f ). Again,
there was an increase in both a- and b-cells in similar pro-
portions (89.8+3.2% b-cells versus 85.5+3.1% in Plk4OE/
Plk4OE; p53KO/p53KO without and with DOX). The size of
the islets directly correlated with the levels of Plk4 transcripts
(figure 2g) and immunostaining of the islets revealed elev-
ated Plk4 protein following treatment of the mice with
doxycycline (figure 2g,h,j) and an increase in centrosome
number (figure 2h,i). Plk4 was present in punctate bodies
corresponding to centrosomes, and these increased in the
number from one such body in non-doxycycline-treated,
p53 þ/þ cells to four or more in p53 null cells over-
expressing Plk4 (figure 2j ). Thus, elevated expression levels
of Plk4 and higher centrosome numbers correlate with
hyperproliferation of a- and b-cells in the pancreas that is
exacerbated in the absence of p53.2.3. Elevated Plk4 over-expression affects melanocyte
differentiation
A striking feature of the Plk4OE/Plk4OE mice was skin lesions
that include alopecia at the time of weaning followed by
regrowth of hair around one month after birth. Animals
that did not lose hair had grey coats (figure 3a,b). Most of
the grey hair did not persist and there was a regain of
some black fur within the first month. This phenotype led
us to examine the effects of Plk4 over-expression upon
melanocytes and the melanin pigment produced by
them. Melanocytes are located in the interfollicular epidermis
and within hair follicles, and differentiate from neural-
crest-derived melanocyte stem cells (MSCs). These MSCs
are intermingled with hair follicle stem cells in the bulge
and the hair germ. Differentiated melanocytes produce and
transfer melanin to the adjacent keratinocytes during the
anagen (growth) phase of the cyclical process of hair regener-
ation (reviewed in [46]). Using Fontana-Masson staining, we
found a reduction of melanin granules in the bulge of
2-day-old Plk4OE/Plk4OE mice and their apparent absence
from follicles, both in a wild-type or p53KO/p53KO back-
ground (figure 3d ). We also stained skin sections to
examine melanin distribution at 20 days. This revealed a
reduction in melanin in Plk4OE/Plk4OE mice irrespective of
whether animals were treated with doxycycline and that
was accentuated if the animals were also null for p53
(figure 3e). As an alternative way to assess melanin pro-
duction, we determined the relative levels of transcripts for
tyrosinase, the enzyme catalysing the first step in melanin
synthesis and which is expressed in melanocytes [47]. Tyrosi-
nase mRNA was reduced both in untreated Plk4OE/Plk4OE
mice that show some elevation of basal Plk4 mRNA levels
and following doxycycline treatment to induce Plk4
expression. Tyrosinase transcripts were further reduced in a
p53 null background (figure 3c). Taken together these obser-
vations point to reduced melanin biosynthesis in response to
elevated Plk4, an effect enhanced in the absence of p53 so
accounting for the grey hair of the animals.
We then wanted to determine whether the grey hair was a
consequence of reduced melanin production or a reduced
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Figure 2. Plk4 over-expression leads to hyperplasia of the pancreatic islets. (a– c) Haematoxylin–eosin-stained sections of mouse pancreas. (a) Control (þ/þ) pancreas
shows normal acinar cells (AC), islets of Langerhans (I) and lobular architecture. (b) Pancreas of Plk4OE/Plk4OE (þDOX) male has normal lobular architecture, intact acinar
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Plk4OE/Plk4OE; p53KO/p53KO male showing normal lobular architecture and very large islets. (d ) Immunofluorescence of pancreas cryosections showing b-cells detected by
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doxycycline treatment. Average from three biological samples (three replicates for each). (h) Proportion of cells showing 1 (one pair of dots), 2 (two pairs of dots)
centrosomes or centrosome amplification (more than two pairs of dots) in pancreatic islets. Centrosomes quantified by counting punctate Cep192 or g-tubulin staining.
(i) Pancreas cryosections stained to reveal E-cadherin (green), centrosome component Cep192 (red in merge; white in monochrome) and DNA (blue). Cell borders
identified by E-cadherin outlined in monochrome image. Note: increase in the number of centrosomes/cell following treatment with doxycycline (þDOX). ( j ) Pancreas
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of P20 back skin cryosections from mice of indicated genotypes and treated with doxycycline where indicated (þDOX). (f ) Anagen hair follicle in wild-type back skin
immunostained to reveal melanocyte markers KIT (red in merge; white, monochrome), MITF (green) and DCT (blue in merge; white in monochrome). DNA is represented
in white. Differentiated melanocytes identified by triple KITþMITFþDCTþ staining. (g) P2 back skin from Plk4OE/Plk4OE mice without or with Plk4 over-expression
(þDOX) showing anagen hair follicle immunostained to reveal melanocyte markers KIT (red in merge; white in monochrome), MITF (green) and DCT (blue in
merge; white in monochrome). DNA is white in merge. Note reduction in differentiated melanocytes identified by triple KITþMITFþDCTþ-positive immunostaining.
(h) P2 back skin from Plk4OE/Plk4OE; p53KO/p53KO mice without or with Plk4 over-expression (þDOX) showing hair follicles immunostained for melanocyte markers
KIT (red in merge; white in monochrome), MITF (green) and DCT (blue in merge; white in monochrome). DNA is white in merge. Differentiated melanocytes
(KITþMITFþDCTþ) are reduced in Plk4OE/Plk4OE; p53KO/p53KO (þDOX) mice. (i) Mean numbers+ s.d. of differentiated melanocytes (KITþMITFþDCTþ) per bulb in
indicated genotypes and treatments. Significance determined by Student’s t-test. *p, 0.05, **p, 0.01 and ***p, 0.005.
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7number of melanocytes undergoing activation/differentiation.
To this end, we carried out immunofluorescence upon cryosec-
tions of the back skin of animals 2 days after birth (P2) to
detect the MSC population undergoing differentiation
(figure 3f– i). The tyrosine kinase receptor, c-KIT and dopa-
chrome tautomerase (DCT) are hallmarks to identify the MSC
population (reviewed in [46]). MSCs co-expressing Kit and
microphthalmia-associated transcription factor (MITF), the
master regulator of melanocyte differentiation (reviewed in
[46]), identify the differentiated melanocyte subpopulation. We
found a reduced number of KITþMITFþDCTþ cells in the
bulge when Plk4 was over-expressed, particularly in a p53KO/
p53KO background (figure 3i). This population is responsible
for pigmentation of growing hair. However, the number of
MSCs (expressing DCT and KIT) in the bulge that will renew
the melanocyte population in subsequent hair cycles did not
vary significantly between the different genotypes and treat-
ments (an average of 4.35–5 KITþDCTþ cells per bulge). This
strongly suggests that Plk4 over-expression compromises
melanocyte differentiation and subsequent melanin synthesis.2.4. Plk4 over-expression affects cell proliferation
in epidermis
The above experiments also revealed a thickening of the epi-
dermis and some apparently invaginated hair follicles when
Plk4 levels were elevated in Plk4OE/Plk4OE; p53KO/p53KO
mice. Thus, we decided to explore the epidermal phenotype
in greater detail. The epidermis is a stratified structure con-
taining self-renewing stem cells within the basal layer that
express keratins 5 and 14 (K5, K14) and that through
delamination and/or asymmetrical cell division give rise to
non-proliferative, spinous and granular layers (expressing
keratins 1 and 10 (K1, K10) and Involucrin) and outer
layers of terminally differentiated stratum corneum cells
(reviewed in [48]). The increased cell density within the
epidermal basal layer of Plk4 over-expressing samples
(figure 3e) prompted us to ask whether cell proliferation
was affected as a result of increased levels of Plk4.
To address whether there was an increased number of
cycling cells within the basal epidermis, we analysed skin
from 2-day-old pups (P2) and 20–day-old pups (P20) using
Ki67 as a marker for proliferating cells (figure 4a–c). In
wild-type skin (þ/þ), Ki67-positive cells are solely found
in the basal layer, as these are the only cycling cells in unper-
turbed circumstances (figure 4a). We found Ki67-positive
cells in the basal layer did not increase significantly following
doxycycline treatment of Plk4OE/Plk4OE mice (n ¼ 300/
sample; 59.5+ 19.4% in Plk4OE/Plk4OE; p53KO/p53KO
versus 63.9+ 9.4% in control (þ/þ)). However, in the skin
of Plk4OE/Plk4OE; p53KO/p53KO mice, doxycycline treatment
also led to the appearance of Ki67-positive cells in the supra-
basal layers (n ¼ 425 cells/sample, 7.40+ 3.90%) within 2
days after birth (asterisk in figure 4a). We also examined
the distribution of keratin 6 (K6), which is normally restricted
to the hair follicles but is also found in the interfollicular epi-
dermis in conditions of hyperplasia the epidermis [49,50].
Strikingly, we found that K6 was widely expressed in basal
and suprabasal cells after induction of Plk4 expression in
either a wild-type or p53 null background (arrowheads in
figure 4a). Whereas in normal skin there is a clear separation
between basal (K5-positive cells) and suprabasal (K10-positive cells) layers, induction of Plk4 expression in either
a wild-type or p53 null background led to an expansion of
K5-positive cells. This was particularly evident in Plk4OE/
Plk4OE; p53KO/p53KO doxycycline-treated mice at 20 days
(figure 4d ), where both Ki67- and K5-positive cells were
significantly expanded to suprabasal layers and K6 staining
extended to most of the epidermis and hair follicles. There
was also an increase in the number of cells expressing the
early differentiation marker, K10.
The above findings were mirrored by the quantitation of
mRNA levels for these markers. Over-expression of Plk4 in
a p53 null background led to a notable increase in the
expression of the basal marker K14 and a reduction in
mRNA levels for involucrin, filaggrin and loricrin, markers
of late stages of differentiation figure 4b). We also found a
reduction of the transcript levels of DNp63, a p53 family
member that controls expansion of epidermal cells and pro-
motes differentiation [51] (figure 4c). This, together with a
similar reduction in expression of the Cdk inhibitor p21
(mp21; figure 4c), is compatible with delayed terminal dif-
ferentiation [52–54]. In agreement, with these results,
percentage of Ki67-positive cells is significantly increased in
Plk4OE/Plk4OE; p53KO/p53KO doxycycline-treated mice at
20 days, suggesting increased proliferation sustains the
higher number of suprabasal cells in these samples compared
to control (figure 4e,f ).
Taken together our findings indicate that elevated
expression ofPlk4 results in hyperproliferation of the epidermis.
Specifically, we observed an expansion of basal progenitor cells
in suprabasal layers and a decreased expression of genes associ-
ated with terminal differentiation. These observations accord
with the thickening of the epidermis and disrupted hair follicle
morphology as a consequence of Plk4 over-expression.
2.5. Plk4 over-expression induces centriole over-
duplication and primary cilia disappearance
in epidermis
We next considered whether the alterations we had observed
in the regulation of cell proliferation and differentiation in the
epidermis could reflect changes mediated by elevated Plk4
upon the centrosomes and/or primary cilia, both of which
rely upon centrioles for their correct formation and function.
To this end, we stained skin sections to reveal acetylated
a-tubulin, a marker of the primary cilia, and Plk4 itself,
which associates with centrioles, either in basal bodies or cen-
trosomes. In the skin of wild-type mice, the great majority of
cells of the basal epidermis showed bodies of Plk4 staining
associated with the base of single primary cilia (figure 5a).
Over-expression of Plk4 during development led to increased
numbers of centrosomes in the basal epidermis and a loss of
primary cilia (figure 5a,c). Loss of primary cilia and mis-posi-
tioning of centrosomes was particularly dramatic when Plk4
over-expression occurred in a p53 null background (12.2+
4.5% of cells with primary cilia in Plk4OE/Plk4OE; p53KO/
p53KO (þDOX) versus 35.3+4.9% in Plk4OE/Plk4OE;
p53KO/p53KO; figure 5a,c). We were still able to observe
some residual primary cilia in hair follicles even though
these cells had extra centrioles (figure 5b). However, consist-
ently, only a single primary cilium was formed (figure 5b),
and these cilia were longer than those in wild-type cells
(figure 5d ). Thus, the effects of elevated Plk4 may differ in
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Figure 4. Plk4 over-expression leads to hyperproliferation and abnormal differentiation of cells in suprabasal layers. (a) Immunofluorescence of cryosections of P2
back skin from mice of indicated genotypes treated with doxycycline as indicated (þDOX). Note: Ki67 reveals proliferating cells in basal and suprabasal (white
asterisk) epidermal layers of Plk4OE/Plk4OE; p53KO/p53KO (þDOX) mice; K6, restricted to hair follicles in controls, is present in epidermis following Plk4 induction
(arrowheads). Basal layer marker K5 present throughout epidermis following Plk4 induction; distribution of early differentiation marker, K10 not affected and does
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epidermal border. (b) Quantitative RT-PCR assays for levels of indicated transcripts in total back skin from 2 day pups of indicated genotypes and treatment (n ¼ 3
and three replicates for each sample). Note: elevated Plk4 transcripts consistently correlate with low expression of late differentiation genes filaggrin (Fla), involucrin
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in Plk4OE/Plk4OE; p53KO/p53KO (þDOX) mice; expanded staining of K5 and K10. (e) Ratio of basal to suprabasal cells indicated as mean+ s.d. ( f ) Proportion of
cycling cells in epidermis. Mean+ s.d. % of cells showing Ki67-positive immunostaining. Significance determined by Student’s t-test. *p, 0.05.
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10different cell types. In the majority of cells of the basal epider-
mis, Plk4 over-expression results in elevated numbers of
centrosomes that form at the expense of primary cilia. This
correlates with the increased proliferation of these cells. A pri-
mary cilium is still able to form alongside additional
centrosomes in some hair follicle cells after Plk4 over-
expression but these primary cilia are abnormal in structure.
We then prepared primary cultures of keratinocytes from
our mouse lines as these can be cultured under conditions
that permit either cell proliferation or, following the addi-
tion of calcium, the formation of cell–cell contacts and
cellular differentiation. Induction of Plk4 over-expressionfollowing addition of doxycycline to primary Plk4OE/Plk4OE-
derived keratinocytes cultured in low concentrations of
calcium reproducibly resulted in centriole over-duplication.
(figure 6a,b). By 48 h after addition of calcium, adherens junc-
tions formed and tight junctions and desmosomes were
assembled. Such cells expressedmarkers of early and late differ-
entiation and grew on top of each other to form a pseudo-three-
dimensional epidermis. Under these conditions, a single
primary cilium formed at the surface of approximately 40% of
cells in either wild-type control cells or in Plk4OE/Plk4OE cells
without Plk4 induction. Addition of doxycycline to the
medium promoted the formation of supernumerary centrioles
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11and the formation of fewer primary cilia (figure 6b,c). When
a primary cilium was formed, there was only one per cell
even though multiple centrioles could be present. Moreover,
these primary cilia were significantly longer than in wild-type
cells or Plk4OE/Plk4OE cells that had not been induced to
over-express Plk4 (figure 6d).
Thus, over-expression of Plk4 results in supernumerary
centrosomes both in cells of the basal epidermis and in cultures
of primary keratinocytes. In both cases, cells appear to fail to
leave the proliferative state and they fail to form primary
cilia. This suggests that over-expression of Plk4 leads to an
alteration in the balance between proliferation and differen-
tiation of the progenitor epidermal cells. Cilia formation
could be compromised either directly by the increased
number of centrosomes or as a consequence of a failure of
cells to cease cycling sufficiently to enable ciliogenesis. It is
known that the primary cilia receive and transmit extracellular
signals during development [55–57] and that several ciliary
mutants display defects in the commitment of progenitors to
differentiate. It is also known that lack of primary cilia in
cells of the basal epidermis would compromise the signalling
events required to promote their correct differentiation [58,59],
so accounting for the defects that we see in cell differentiation
in the skin of Plk4 over-expressing mice.3. Discussion
The great majority of tumour cells are both aneuploid and
have multiple centrosomes [7,8,60], leading to the suggestion
that these properties may be causally related. However, the
extent to which chromosome instability resulting from mul-
tiple centrosomes contributes to tumour formation is not
clear because centrosome clustering at mitosis usually
ensures the fidelity of chromosome transmission on bipolar
spindles [61]. The transgenic mouse we have generated
allows us to induce centriole duplication in response to
elevated Plk4 and so begin to address the relationship
between multiple centrosomes and tumour formation. Our
findings that elevating Plk4 perturbs the balance between
proliferation and differentiation in different tissues in a
manner exacerbated by loss of the p53 tumour suppressor
gives the potential to identify links between supernumerary
centrosomes and early steps in tumourigenesis.
Mice deficient for p53 are susceptible to tumour formation
[62] and, moreover, the embryonic fibroblasts established
from such mice show supernumerary centrosomes [63]. One
interpretation of these findings has been that p53mightmediate
cell cycle arrest in response to increased centrosome numbers as
part of a tetraploidy checkpoint to monitor completion of cyto-
kinesis [64] or bymonitoringDNAdamage or spindle defects in
these cells [65–67]. Others have proposed a direct role for p53 in
directly regulating centrosome duplication [68–70]. While it
remains difficult to distinguish cause from effect, growing evi-
dence points towards a p53-mediated response to changes in
centrosome integrity that receives support from our present
study and earlier findings. p53 deletion overcomes either the
block to cell progression or apoptosis resulting from depletion
of several different centrosome proteins in cultured cells [71]
or centriole loss in Sas4 knockout mouse embryos [34]. More-
over, recent studies have identified a p53 response that is
triggered by the inhibition or the destruction of Plk4 that pre-
vents centriole duplication [33,35]. DNA damage, stress,chromosome mis-segregation, prolonged time in mitosis
[33,35], nor the Hippo-signalling pathway, recently shown to
respond to cytokinesis failure [72], were responsible for trigger-
ing this p53-dependent arrest in a senescent-like G1 state in
response to centrosome loss. We now show that defects in the
pancreas and skin resulting from Plk4 over-expression are
enhanced by the loss of p53. We do not know the nature of
this p53-dependent response to either gain or loss of centro-
somes but it seems possible that it uses a common pathway as
both situations can perturb spindle organization and dynamics
and cell cycle progression.
The tumour formation that we observe, however, appears
dependent upon the loss of p53 function; it is exacerbated by
Plk4 over-expression but is not seen following Plk4 over-
expression alone. It will be important in future studies to
identify the origins of these tumour cells, particularly the sar-
comas that appear with increased frequency when Plk4 levels
are elevated. That we see tissue hyperplasia rather than neo-
plasia in the pancreas and skin might reflect the time course
of the development of different tumour types in the absence
of p53. Usually, p53 null mice first develop lymphomas and
most do not survive for long enough for sarcomas to arise.
Nevertheless, sarcoma formation predominates in mice in
which lymphocytes have been genetically eliminated and it
is conceivable that the development of carcinomas, as
would occur in the skin, would be masked by these earlier
events of lymphoma and then sarcoma formation [73].
The hyperplasia we observe in the pancreas in response to
elevated Plk4 and enhanced in the absence of p53 appears to
affect the differentiated endocrine cells equally. Thus, the
enlarged islets of Langerhans maintain similar proportions of
a- and b-cells suggesting that both populations have prolifer-
ated and differentiated. In the skin, on the other hand,
elevated Plk4 permits proliferating cells to expand into the
suprabasal layers of the epidermis where they show inap-
propriate expression of differentiation markers. This too is
enhanced in a p53 background. The shift in the balance of
cell proliferation and differentiation could reflect persistence
of the centriole as a structure associated with the centrosome
and so keeping the cell prepared for cell division. It could
also result from a loss of barrier function due to the disruption
in the stratified epidermal architecture as occurs, for example,
in the inflammatory response (reviewed in [74]). The stratifica-
tion of the skin occurs when polarized cells of the basal
epidermis undergo divisions perpendicular to the basal cell
layer to produce the differentiating upper layers [75]. Multiple
centrosomes might affect the orientation of mitotic spindles
thus perturbing the mechanism that delivers cells from the
basal to the suprabasal layers in an orderly manner.
Alternatively, the abnormal differentiation in Plk4 over-
expressing, p53 null cells could reflect loss of primary cilia
that we observe to reciprocate additional centrosome for-
mation both in cells of the basal epidermis and in cultures
of primary keratinocytes established from this skin. The differ-
entiation of cells entering the spinous layer is a Notch
signalling-dependent process [76] and a failure of ciliogenesis
has been reported to compromise Notch signalling and result
in defective epidermal differentiation [58]. Thus, in the absence
of sufficient primary cilia, the signalling pathways required for
correct differentiation would be defective. Reduced signalling
activity was also previously reported in cultured cells expres-
sing elevated levels of Plk4 [77]. However, in the examples
studied by these authors, cells with extra centrosomes often
Table 1. Primers for mPlk4 and genotyping.
mPlk4RosaFor 50GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGGCGGCGTGCATCGGGGAGAGGATCGAGGACTTTAAG30
mPlk4RosaRev 50GGGGACCACTTTGTACAAGAAAGCTGGGTTTAGGAGTTGGATTAGAAAACATCAGAAGGATGGAAGAAAG30
Plk4Insert_Forward 50CCGCGCCTGTCCTTTCTCCC30
Plk4Insert_Reverse 50GTCCGGCCAGGACGACGAGG30
Wt_Rosa_locus 50GGCAAGCACCACCACTGGCTGGC30
Wt_Rosa_locus 50GAAGTGTAACTGTGGACAGAGGAGCC30
IMR8306_p53Mut_FW 50CTATCAGGACATAGCGTTGG30
IMR7778_p53_Rev 50ATACTCAGAGCCGGCCT’30
IMR7777_p53_FW 50ACAGCGTGGTGGTACCTTAT30
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12formed more than one primary cilium. These cilia were associ-
ated with reduced concentrations of signalling molecules and
this appeared to be responsible for the reduction in signalling
activity. This contrasts to our findings in keratinocytes where
supernumerary centrosomes appear to form at the expense
of the formation of cilia. The occasional cell that we do find
with two primary cilia of increased length seems at odds
with these earlier findings. The net outcome of disrupted sig-
nalling is the same although in one case it appears to be the
consequence of the inefficient operation of the signalling
machinery and in the other through the loss of the mechanical
apparatus, the cilia themselves.
In addition to the work we now report, another study has
described a p53-dependent response to mitotic abnormalities
resulting from Plk4 over-expression in the developing mouse
brain [42]. These authors described how this led neural stem
cells to undertake multipolar mitoses leading to aneuploid
cells that were directed to p53-dependent apoptosis. They
reported that loss of p53 allowed aneuploid cells to accumulate
and differentiate thereby reducing the proportion of proliferat-
ing cells and reducing brain size. These consequences seem to
differ from the ones we now report in the pancreas and
skin where p53 enhances the effects of Plk4 over-expression
by allowing cells to proliferate. This suggests that the
responses to the supernumerary centrosomes resulting from
over-expression of Plk4 might differ in different tissues.
Our study highlights the importance of the p53 pathway
in monitoring defects elicited by the elevated expression of
Plk4. The increase in centrosome numbers and decrease in
primary cilia strongly suggest that the effects we observe
reflect the principal function of Plk4 to drive centrosome
duplication, although we cannot at this stage exclude an
involvement of Plk4 in regulating other aspects of cellular
physiology (e.g. [78,79]). Further studies are now required
to dissect out the precise manner by which the p53 pathway
is triggered together with the mechanisms whereby elevated
Plk4 affects cell cycle progression and cellular architecture,
how these might affect the differentiation programme of the
cell and how this could contribute to tumour development.4. Material and methods
4.1. Generation of mESCs inducibly expressing Plk4
from the Rosa26 locus
The rtTA gene and response element (ClonTech) were cloned
into a Rosa26 targeting vector [80] upstream of Gatewayelements attR1/attR2. mPlk4 cDNA flanked by attL1/attL2
sites was introduced into the vector by Gateway cloning
(Life Technology), yielding a Rosa26 targeting vector
harbouring tetracycline-inducible cDNA for Plk4. Primers
used for subcloning the mousePlk4cDNA were mPlk4Rosa-
For and mPlk4RosaRev (table 1). The targeting vector was
introduced into JM8 mESCs by electroporation, and success-
ful integrations were selected for with 1 mg ml21 puromycin.
Correct targeting was confirmed by long-range PCR across
the 50 homology arm of clonal puromycin-resistant cell lines.
4.2. Histological analysis of skin and pancreas
Samples were fixed in 4% paraformaldehyde in PBS at 48C
overnight and then dehydrated and embedded in paraffin
wax. Eight micrometre sections were stained with haema-
toxylin and eosin for histological analysis. Samples from
dorsal skin or pancreas were washed in PBS, embedded in
OCT compound and kept at 2808C prior to cryosectioning
for immunofluorescence.
4.3. Fontana-Masson staining
Fontana-Masson staining of backskin cryosections was per-
formed following the protocol provided in the Fontana-Masson
kit (Abcam, ab150669).
4.4. Culture of kerotinocytes
Mouse keratinocytes were isolated from the backskin of 2-
day-old pups from each genetic background using dispase
and trypsin. After filtration in 40 mm cell strainers, cells
were cultured in low calcium medium (50 mM Ca2þ) on
plates coated with coating matrix (Gibco) as previously
described [81]. Once confluency was reached, coverslips
were either fixed in2208Cmethanol to visualize centrosomes
or cultures were shifted to 2 mM Ca2þ media for 48 h to
analyse cytoskeleton and primary cilium formation.
4.5. Antibodies
Primary antibodies were obtained from the following sources:
rabbit anti-Cep192 [82] (1 : 1000), rabbit anti-keratin 5 ab52635
(Abcam, 1 : 1000), chicken anti-keratin 5 #905901 (BioLegend,
1 : 1000), rabbit anti-keratin 10 ab76318 (Abcam, 1 : 1000),
rabbit anti-keratin 6 #905701 (BioLegend, 1 : 1000), rabbit
anti-cKit ab5506 (Abcam), rabbit anti-Ki67 ab15580
(Abcam, 1 : 500), mouse anti-g-tubulin monoclonal GTU-88
Table 2. Primers for RT-QPCR.
Plk4 forward 50AGGAGAAACTAATGAGCACCACA30
Plk4 reverse 50TGGCTCTCGTGTCAGTCCAA30
GAPDH forward 50AAGGTCATCCCAGAGCTGAA30
GAPDH reverse 50CTGCTTCACCACCTTCTTGA30
K1 forward 50GAACACTAAGCTGGCCCTGGACAT30
K1 reverse 50CCTCGGGAGTAACTGGTGGAAACA30
K5 forward 50CAGTGTGCCAACCTCCAGAACG30
K5 reverse 50AGCCCGCTACCCAAACCAAGAC30
K10 forward 50GGAGGGTAAAATCAAGGAGTGGTA30
K10 reverse 50TCAATCTGCAGCAGCACGTT30
K14 forward 50GACGCCGCCCCTGGTGTG30
K14 reverse 50 GGTGGCGATCTCCTGCTC30
ﬁlagrin forward 50GGAGGCATGGTGGAACTGA30
ﬁlagrin reverse 50TGTTTATCTTTTCCCTCACTTCTACATC30
involucrin forward 50GTCCGGTTCTCCAATTCGTGTTT30
involucrin reverse 50GCAATTGGAAGAGAAGCAGCATCAG30
loricrin forward 50TCACTCATCTTCCCTGGTGCTT30
loricrin reverse 50GTCTTTCCACAACCCACAGGA30
DNp63 forward 50CTGGAAAACAATGCCCAGAC30
DNp63 reverse 50GAGGAGCCGTTCTGAATCTG30
mp21_forward 50GTGGGTCTGACTCCAGCCC30
mp21_reverse 50CCTTCTCGTGAGACGCTTAC30
tyrosinase forward 50GCGAAGGCACCGCCCTCTTT30
tyrosinase reverse 50TCCCACCAGTGCTGCCCCAA30
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13(Sigma, 1 : 200), rabbit anti-g-tubulin T3559 (Sigma, 1 : 500), rat
anti-PLK4 [78] (1 : 1000), mouse anti-centrin2/3 S3332 (Santa
Cruz Biotechnology, 1 : 500), guinea-pig anti-insulin ab7842
(Abcam, 1 : 50), mouse monoclonal anti-glucagon ab10988
(Abcam, 1 : 200), mouse monoclonal anti-acetylated-tubulin
clone 6-11B-1 (Sigma, 1 : 200), mouse anti-MITF ab80651
(Abcam, 1 : 200), rabbit anti-DCT ab74073 (Abcam, 1 : 200),
mouse anti-E-cadherin clone ECDD-2 (Invitrogen, 1 : 200), rat
anti-mouse-cKIT clone 2B8 (Biolegend). Secondary antibodies
used (1 : 2000 for immunofluorescence) were conjugated with
Alexa 488, Alexa 568 orAlexa 647 (Invitrogen) andhadminimal
cross-reactivity to other species.
4.6. Fixation protocol for tissues and cells
For identification of centrosomal proteins by immuno-
fluorescence, preparations were fixed (12 min in ice-cold
methanol), quickly rinsed in 1PBS and then permeabilized
in 1PBS; 0.1% Triton-X100 for three times, for 5 min each.
Preparations were blocked with 1PBS; 0.1% Tween 20;
10% FBS for 1 h, followed by primary antibody incubation
in the same solution for at least 2 h at room temperature.
Washes were performed in 1PBS; 0.1% Tween 20 for
30 minutes before the addition of secondary antibody in
1PBS; 0.1% Tween 20 with 10% FBS. Preparations were
washed as previously, mounted in Vectashield with DAPI
and sealed.
4.7. Microscopy
Images were collected on a Zeiss LSM 510 Meta Laser Scan-
ning Confocal Microscope using 63X/1.4 or 100X/1.4 oil
objectives, and the LSM 510 v. 4.2 software. Images were
deconvolved using HUYGENS PROFESSIONAL software; proces-
sing and analysis was performed with IMAGEJ v. 1.50b and
Adobe PHOTOSHOP CS5.
4.8. RT-qPCR conditions
RNAwas isolated from the different tissues with RNAqueous
Kit (Ambion) and RT-QPCR was performed using Power
SYBRw Green RNA-to-CTTM 1-Step Kit (Life Technologies)
on a Stepone Plus 96 RT system (Life Technologies) with
GAPDH as reference gene. Primers pairs (forward and
reverse) used for each gene are indicated in table 2. Specificity
was confirmed by subsequent melting curve analysis or gel
electrophoresis. Levels of PCR product were expressed as a
function of GAPDH. Reactions were performed in triplicatefor at least three biological samples and fold changes calcu-
lated using the 22DDCT method.Competing interests. We declare we have no competing interests.
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